| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 174,773 | 281,927 | ||
| Short-term marketable securities | 154,907 | 56,877 | ||
| Receivables from collaborative arrangements | 18,267 | 21,919 | ||
| Other prepaid and current assets | 6,750 | 5,571 | ||
| Total current assets | 354,697 | 366,294 | ||
| Long-term marketable securities | 3,029 | - | ||
| Property and equipment, net | 6,257 | 6,641 | ||
| Operating lease assets | 25,450 | 26,493 | ||
| Restricted cash | 836 | 836 | ||
| Other assets | 25,191 | 25,771 | ||
| Total assets | 415,460 | 426,035 | ||
| Accounts payable | 2,213 | 1,675 | ||
| Accrued personnel-related expenses | 10,330 | 7,259 | ||
| Accrued clinical and development expenses | 5,842 | 3,783 | ||
| Accrued general and administrative expenses | 2,699 | 2,459 | ||
| Operating lease liabilities | 10,914 | 10,896 | ||
| Income tax payable | 4,074 | 26,696 | ||
| Other accrued liabilities | 1,335 | 1,865 | ||
| Total current liabilities | 37,407 | 54,633 | ||
| Long-term operating lease liabilities | 33,681 | 35,561 | ||
| Future royalty payment contingency | 32,213 | 31,640 | ||
| Unrecognized tax benefits | 79,165 | 77,805 | ||
| Other long-term liabilities | 313 | 1,548 | ||
| Ordinary shares, 0.00001 par value per share 200,000 shares authorized 50,672 and 49,471 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 1 | 1 | ||
| Additional paid-in capital | 1,153,299 | 1,149,123 | ||
| Accumulated other comprehensive income | 32 | -10 | ||
| Accumulated deficit | -920,651 | -924,266 | ||
| Total shareholders' equity | 232,681 | 224,848 | ||
| Total liabilities and shareholders' equity | 415,460 | 426,035 | ||
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)